 |
|
Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort
Yi-Wen Ting, Amanda Shen-Yee Kong, Shamsul Mohd Zain, Wah-Kheong Chan, Hwa-Li Tan, Zahurin Mohamed, Yuh-Fen Pung, Rosmawati Mohamed
Clin Mol Hepatol. 2021;27(3):486-498. Published online 2021 Feb 23 DOI: https://doi.org/10.3350/cmh.2020.0162
|
|
Citations to this article as recorded by
 Ethnic differences in metabolic and histologic features among White, Hispanic, Black and Asian patients with metabolic-associated Steatotic liver disease: A network meta-analysis
Limin Lin, Jiaming Lai, Ling Luo, Junzhao Ye, Bihui Zhong
Annals of Hepatology.2025; 30(2): 101780. CrossRef Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction–Associated Steatotic Liver Diseases: A Pathway to Precision Medicine
Xiang Zhang, Kyong-Mi Chang, Jun Yu, Rohit Loomba
Annual Review of Pathology: Mechanisms of Disease
.2025; 20(1): 375. CrossRef Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease
Jun-Jie Wang, Xiao-Yuan Chen, Yi-Rong Zhang, Yan Shen, Meng-Lin Zhu, Jun Zhang, Jun-Jie Zhang
Frontiers in Physiology.2025;[Epub] CrossRef Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
Mohammad Shafi Kuchay, Narendra Singh Choudhary, Bruno Ramos-Molina
American Journal of Physiology-Cell Physiology.2025; 328(5): C1637. CrossRef 17-Beta-Hydroxysteroid Dehydrogenase 13 Loss of Function Does Not Confer Protection to Nonalcoholic Fatty Liver Disease in Indian Population
Bale Govardhan, V. Kulkarni Anand, Padaki Nagaraja Rao, P. Balachandran Menon, Sharma Mithun, Mitnala Sasikala, T.R. Sowmya, Sekaran Anuradha, C. Pawar Smita, D. Nageshwar Reddy, Vishnubhotla Ravikanth
Journal of Clinical and Experimental Hepatology.2024; 14(4): 101371. CrossRef GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients
Ernest A. Adeghate
Expert Opinion on Pharmacotherapy.2024; 25(3): 223. CrossRef Emerging roles of RNA‐binding proteins in fatty liver disease
Oluwafolajimi Adesanya, Diptatanu Das, Auinash Kalsotra
WIREs RNA.2024;[Epub] CrossRef Are we ready for genetic testing in metabolic dysfunction‐associated steatotic liver disease?
Adele Tulone, Grazia Pennisi, Carlo Ciccioli, Giuseppe Infantino, Claudia La Mantia, Roberto Cannella, Francesco Mercurio, Salvatore Petta
United European Gastroenterology Journal.2024; 12(5): 638. CrossRef Genetic predisposition to metabolic dysfunction-associated fatty liver disease
O.E. Abaturov, A.O. Nikulina
CHILD`S HEALTH.2024; 19(3): 162. CrossRef Interaction Between PNPLA3 and SIRT5 Genetic Variants in Association with Liver Fibrosis Severity in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
Kamonchanok Moonlisarn, Pornjira Somnark, Bootsakorn Boonkaew, Chalermarat Bunchorntavakul, Pisit Tangkijvanich
Genes.2024; 15(11): 1370. CrossRef Non-alcoholic fatty liver disease establishment and progression: genetics and epigenetics as relevant modulators of the pathology
Camila Cristiane Pansa, Letícia Ramos Molica, Karen C. M. Moraes
Scandinavian Journal of Gastroenterology.2023; 58(5): 521. CrossRef Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD
Maral Amangurbanova, Daniel Q. Huang, Rohit Loomba
Alimentary Pharmacology & Therapeutics.2023; 57(1): 37. CrossRef Geographical similarity and differences in the burden and genetic predisposition of NAFLD
Terry Cheuk‐Fung Yip, Eduardo Vilar‐Gomez, Salvatore Petta, Yusuf Yilmaz, Grace Lai‐Hung Wong, Leon A. Adams, Victor de Lédinghen, Silvia Sookoian, Vincent Wai‐Sun Wong
Hepatology.2023; 77(4): 1404. CrossRef Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
Seung Min Lee, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(1): 171. CrossRef Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science
Sven Thamm, Marina K. Willwacher, Gary E. Aspnes, Tom Bretschneider, Nicholas F. Brown, Silke Buschbom-Helmke, Thomas Fox, Emanuele M. Gargano, Daniel Grabowski, Christoph Hoenke, Damian Matera, Katja Mueck, Stefan Peters, Sophia Reindl, Doris Riether, Ma
Journal of Medicinal Chemistry.2023; 66(4): 2832. CrossRef Comparison between obese and non-obese nonalcoholic fatty liver disease
Wah-Kheong Chan
Clinical and Molecular Hepatology.2023; 29(Suppl): S58. CrossRef Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD
Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim
Alimentary Pharmacology & Therapeutics.2023; 58(2): 229. CrossRef Polymorphisms of HSD17B13, GCKR, HFE, and CP as factors of the development of non-alcoholic fatty liver disease and comorbid diseases
O. V. Smirnova, D. V. Lagutinskaya
Meditsinskiy sovet = Medical Council.2023; (8): 119. CrossRef Food Network Analysis in Non-Obese Patients with or without Steatosis
Rossella Donghia, Pasqua Letizia Pesole, Sergio Coletta, Caterina Bonfiglio, Giovanni De Pergola, Sara De Nucci, Roberta Rinaldi, Gianluigi Giannelli
Nutrients.2023; 15(12): 2713. CrossRef Associations between genetic variants of HSD17B13 and fasting plasma glucose in Chinese children
Ping-ping Zhang, Jie-yun Song, Li Li, Miao Xu, Hui Wang, Hai-jun Wang
Nutrition, Metabolism and Cardiovascular Diseases.2023; 33(9): 1778. CrossRef Advances in genetic variation in metabolism-related fatty liver disease
Fan Shi, Mei Zhao, Shudan Zheng, Lihong Zheng, Haiqiang Wang
Frontiers in Genetics.2023;[Epub] CrossRef Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches
Eirini Martinou, Marinos Pericleous, Irena Stefanova, Vasha Kaur, Angeliki M. Angelidi
Diagnostics.2022; 12(2): 407. CrossRef Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Algera Goga, Markus Stoffel
Nature Reviews Drug Discovery.2022; 21(6): 417. CrossRef Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients
Antonio Gil-Gómez, Ángela Rojas, María R. García-Lozano, Rocío Muñoz-Hernández, Rocío Gallego-Durán, Douglas Maya-Miles, Rocío Montero-Vallejo, Sheila Gato, Javier Gallego, Rubén Francés, Germán Soriano, Javier Ampuero, Manuel Romero-Gómez
International Journal of Molecular Sciences.2022; 23(19): 11840. CrossRef Update on genetics and epigenetics in metabolic associated fatty liver disease
Xiaopeng Zhu, Mingfeng Xia, Xin Gao
Therapeutic Advances in Endocrinology and Metabolism.2022;[Epub] CrossRef No evidence for a causal link between Helicobacter pylori infection and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study
Yuwei Liu, Hongqin Xu, ZiHan Zhao, Yutong Dong, Xiaomei Wang, Junqi Niu
Frontiers in Microbiology.2022;[Epub] CrossRef Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis
Shan Tang, Jing Zhang, Ting-Ting Mei, Wen-Yan Zhang, Su-Jun Zheng, Hai-Bin Yu
BMC Gastroenterology.2021;[Epub] CrossRef An analysis of polygenic risk scores for non-alcoholic fatty liver disease
Dae Won Jun
Clinical and Molecular Hepatology.2021; 27(3): 446. CrossRef
|